A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Phase 2
38
about 4.2 years
18+
1 site in OH
About this study
This trial is testing a new treatment, NovoTTF-200T(P), when combined with gemcitabine and nab-paclitaxel for people with resectable pancreatic cancer. Patients will receive these treatments in cycles followed by surgery to remove the tumor if possible. The goal is to see how well this combination works.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Gemcitabine
- 2.Take Nab paclitaxel
- 3.Use NovoTTF-200T(P)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
injection (Injection), infusion
Primary: 2 Year Overall Survival (OS)
Secondary: Assess adverse events, Overall Response Rate (ORR), Overall Survival (OS), Post Resection Disease Free Survival (DFS)
therapeutic
Oncology